From Washington, DC

• The American Hospital Association informs us,
  • “Republicans on the House Energy and Commerce, Ways and Means, and Education & Workforce Committees have released a summary of draft legislation the committees could introduce as soon as this week. The Lower Costs, More Transparency Act includes provisions focused on health care price transparency, site-neutral payment cuts, and extending certain funding set to expire Sept. 30 for Community Health Centers, the National Health Service Corps and the Teaching Health Centers Graduate Medical Education Program. The bill also would delay for two years the start of Medicaid Disproportionate Share Hospital cuts scheduled to take effect on Oct. 1.”

• CMS changed its No Surprises Act announcement to read
  • Effective September 5, 2023, the Departments have directed certified IDR entities to proceed with eligibility determinations for single and bundled disputes submitted on or before August 3, 2023.  All other aspects of Federal IDR process operations remain suspended. Disputing parties may continue to engage in open negotiation. 

• The FEHBlog noticed on reginfo.gov that the following two No Surprises Act proposed regulations were submitted for Office of Information and Regulatory Affairs review on August 29:
  • AGENCY: HHS-CMS RIN: 0938-AV15 Status: Pending Review
  • TITLE: Independent Dispute Resolution Operations (CMS-9897)
  • STAGE: Proposed Rule SECTION 3(f)(1) SIGNIFICANT: Yes
  • RECEIVED DATE: 08/29/2023 LEGAL DEADLINE: None
  • and
  • AGENCY: HHS-CMS RIN: 0938-AV39 Status: Pending Review
  • TITLE: Federal Independent Dispute Resolution Process Fees (CMS-9890)
  • STAGE: Proposed Rule SECTION 3(f)(1) SIGNIFICANT: Yes
  • RECEIVED DATE: 08/29/2023 LEGAL DEADLINE: None
• The first Interested party meetings with OIRA are scheduled for September 8.

From the public health front,

• The American Hospital Association tells us
  • “The Centers for Disease Control and Prevention Sept. 5 alerted clinicians to a recent increase in respiratory syncytial virus in the Southeastern U.S., which could signal the beginning of the 2023-2024 RSV season nationally. CDC encourages clinicians to prepare to implement prevention options, including the new long-acting monoclonal antibody to protect infants and some young children at higher risk for severe disease and two new vaccines to protect older adults from severe disease.”

• Per STAT News
  • “More older adults have been hospitalized for COVID-19 over the past several weeks, according to internal data reviewed by health insurance giant Humana.
  • “Humana, which mostly provides health insurance to those 65 and older and who are therefore more vulnerable to the worst effects of Covid, expected more Covid cases and hospitalizations this year. But it didn’t expect the uptick to come during the waning summer months.”

• BioPharma Dive reports,
  • Moderna said that an updated COVID shot it’s developing can protect against a form of the coronavirus known as BA.2.86, or Pirola, adding to early evidence the emerging variant may not be as troublesome as scientists had feared.
  • The data, delivered in a press release on Wednesday, show that the vaccine helped spur an immune response in humans against Pirola. It follows an announcement by Moderna last month that the same vaccine appears protective against other currently circulating strains known as Eris and Formax.
  • The Food and Drug Administration is currently reviewing the booster shot, with a decision expected shortly.

• MedPage Today explains how to navigate the fall vaccine season for COVID-19, the flu, and RSV.

From the U.S healthcare business front,

• Health Payer Intelligence points out four essential components of chronic disease management strategies.
  
• Healthcare Dive relates,
  • Salt Lake City-based Intermountain Health last week reported $184 million in operating income for the first half of 2023, a 35% decrease from the prior-year period when the health system posted an operating income of $285 million. 
  • Expenses climbed to a total of $7.4 billion, offsetting a 22% year-over-year increase in revenue. Intermountain logged nearly $8 billion of revenue for the first six months of the year. 
  • The nonprofit operator still inked nearly $1.1 billion in net gain in the first half of the year, driven by investment income of $909 million.

• Per MedTech Dive,
  • “Abbott reached an agreement to acquire Bigfoot Biomedical, a company that makes smart insulin pen caps that can sync with continuous glucose monitors to provide dose recommendations.
  • “The companies did not disclose the price of the acquisition, but plan to close it in the third quarter, they said in a Tuesday announcement. 
  • “The planned purchase would be Abbott’s first insulin delivery technology, adding to its position as one of the top CGM makers.”